NCT01534052View on ClinicalTrials.gov

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

PHASE2CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

April 18, 2017

Study Completion Date

April 18, 2017

Conditions

Castration-Resistant Prostate Cancer (CRPC)

Interventions

DRUG

Enzalutamide

Oral

Trial Locations (7)

6001

Site ZA2702, Port Elizabeth

6529

Site ZA2701, George

15215

Site US105, Pittsburgh

60637

Site US104, Chicago

78253

Site US106, San Antonio

80045

Site US107, Aurora

Unknown

Site MD37301, Chisinau

Sponsors

Lead Sponsor

Astellas Pharma Inc

All Listed Sponsors

collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY